Johnson & Johnson submits EUA for COVID-19 vaccine

Johnson & Johnson submits EUA for COVID-19 vaccine

Johnson & Johnson applies to FDA for an EUA for its single-shot Janssen COVID-19 vaccine candidate
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

NEW BRUNSWICK, NJ—Johnson & Johnson recently stated that Janssen Biotech has submitted an application to the FDA, requesting Emergency Use Authorization (EUA) for its investigational single-dose Janssen COVID-19 vaccine candidate. The EUA submission is based on topline efficacy and safety data from the company’s Phase 3 ENSEMBLE clinical trial, which has demonstrated that the investigational single-dose vaccine met all primary and key secondary endpoints. Johnson & Johnson says that the company expects to have product available to ship immediately, following authorization.

“[The] submission for Emergency Use Authorization of our investigational single-shot COVID-19 vaccine is a pivotal step toward reducing the burden of disease for people globally and putting an end to the pandemic. Upon authorization of our investigational COVID-19 vaccine for emergency use, we are ready to begin shipping,” explained Dr. Paul Stoffels, vice chairman of the executive committee and chief scientific officer at Johnson & Johnson. “With our submission to the FDA and our ongoing reviews with other health authorities around the world, we are working with great urgency to make our investigational vaccine available to the public as quickly as possible.”

Johnson & Johnson has initiated rolling submissions with several health agencies outside the US, and will submit a Conditional Marketing Authorization Application with the European Medicines Agency in the coming weeks.

The Janssen investigational vaccine is compatible with standard vaccine distribution channels. If authorized, the investigational single-dose vaccine is estimated to remain stable for two years at -4°F (-20°C), and the vaccine can be stored for at least three months at standard refrigerators at temperatures of 36°F–46°F (2°-8°C). Johnson & Johnson will be able to ship the vaccine using the same cold chain technologies it generally uses to transport other medicines.

Janssen’s COVID-19 vaccine was created using Johnson & Johnson’s AdVac vaccine platform, which was also used to develop and manufacture Janssen’s European Commission-approved Ebola vaccine regimen. The platform has additionally been used to construct the company’s investigational Zika, RSV, and HIV vaccines. The safety profile observed for the COVID-19 vaccine was consistent with other investigational vaccines using the AdVac technology.

Research and development activities for the investigational Janssen COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the US, has been funded in whole or in part by federal funds from the US Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, in collaboration with the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health.

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
A starry night sky reflected over calm water, symbolizing the discovery of hidden patterns in complex systems.

Technology Guide: Spatial biology techniques

Discover essential strategies and expert insights to navigate the expanding world of spatial biology.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue